|
|
|
| Pre-treatment drug resistance of newly reported HIV-1 infected individuals in Wenzhou |
| ZHU Chuanxin*, ZHENG Wenli, JIN Congnan, SU Feifei, WU Maomao, SUN Baochang, ZHANG Jiafeng
|
| *Wenzhou Center for Disease Control, Prevention, Wenzhou, Zhejiang325000, China |
|
|
|
|
Abstract Objective To know the pre-treatment drug resistance ( PDR ) status of newly reported human immunodeficiency virus type 1 ( HIV-1 ) infected individuals in Wenzhou, so as to provide guidance for antiretroviral therapy ( ART ). Methods Totally 232 plasma samples of newly reported HIV-1 infected individuals who had not received ART were collected in Wenzhou in 2019. Virus ( HIV-1 ) RNA was extracted, followed by reverse transcription PCR and nested PCR to amplify the pol region and sequence. Resistance mutations and resistance to non-nucleoside reverse transcriptase inhibitors ( NNRTIs ), nucleoside reverse transcriptase inhibitors ( NRTIs ) and protease inhibitors ( PIs ) was analyzed. Results The pol region sequences from 199 infected patients were obtained and the incidence of PDR was 8.04% ( 16/199 ). Eight genotypes were detected, including circulating recombinant forms ( CRFs ) CRF07_BC ( 47.24%, 94/199 ) and CRF01_AE ( 29.15%, 58/199 ) which were the dominant types. Two unique recombinant forms ( URFs ) were detected, namely URF( CRF01_AE/BC ) and URF( B/C ) . Thirty-one cases ( 15.58% 31/199 ) had drug-resistant mutations. For NNRTIs, NRTIs and PIs, 20 cases ( 64.52% ) , 2 cases ( 6.45% ) and 9 cases ( 29.03% ) with drug resistance mutations were detected, respectively. The resistance mutations to NNRTIs included K101E, K103N/R, V106I, E138K, V179D/E/T, Y181C, G190A and H221Y. Four cases each had two resistance mutations to NNRTIs. The resistance mutations to NRTIs were V75M and M184V. The resistance mutations to PIs were M46I, L33F and Q58E. For the newly released NNRTI drug Doravirine ( DOR ), two cases were found to have mutations of resistance. Conclusions The incidence of PDR among newly reported HIV-1 patients in Wenzhou is 8.04%, mainly caused by NNRTIs drug-resistant mutation. Resistance to the new drug DOR has emerged. The surveillance of drug resistance should continue to be strengthened.
|
|
Received: 30 December 2020
Revised: 08 February 2021
Published: 12 May 2021
|
|
|
|
|
|
[1] 吴亚松,马烨.HIV耐药评估和预防策略[J].传染病信息,2017,30(6):351-354.
[2] World Health Organization. HIV drug resistance surveillance guidance: updated 2015[EB/OL].(2017-10-29)[2021-02-08].http://apps.who.int/iris/bitstream/10665/204471/1/9789241510097eng.pdf?ua=1.
[3] World Health Organization.Surveillance of HIV drug resistancein adults initiating antiretroviral therapy(Pre-treatment HIV drugresistance)[EB/OL].(2017-05-08)[2021-02-08].http://apps.who.int/iris/bitstream/10665/112802/1/9789241507196eng.pdf?ua=1.
[4] 刘佳,许巍,何翠,等.河南省新确证HIV感染者中HIV原发耐药状况研究[J].中华流行病学杂志,2016,37(5):643-647.
[5] 陈孙云,郭春辉,吴楠楠,等.江阴市HIV-1感染者亚型及原发耐药基因突变研究[J].中华实验和临床病毒学杂志,2018,32(4):377-381.
[6] World Health Organization.WHO HIV drug resistance report 2012[EB/OL].[2021-02-08].http://www.who.int/hiv/pub/drugresistance/report2012/en.
[7] ZHAO S,FENG Y,HU J,et al.Prevalence of transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China[J].Sci Rep,2018,8(1):12273.
[8] 叶振淼,金茜,王大勇,等.1985—2016年浙江省温州市艾滋病病毒感染者/艾滋病患者生存时间及影响因素分析[J].疾病监测,2017,32(7):557-562.
[9] ZHANG J,GUO Z,YANG J,et al.Genetic diversity of HIV-1 and transmitted drug resistance among newly diagnosed individuals with HIV infection in Hangzhou,China[J].J Med Virol,2015,87(10):1668-1676.
[10] 孙伟东,姜天俊,黄辉煌,等.北京地区HIV-1感染者治疗前耐药特征及2年抗病毒治疗效果研究[J].国际病毒学杂志,2020,27(3):224-227.
[11] XU Y,PENG X,PENG X,et al.Characterization of HIV-1 subtypes and transmitted drug resistance among treatment-naive HIV-infected individuals in Zhejiang, China, 2014-2017[J].Arch Virol,2018,163(8):2233-2237.
[12] 曹栋卿,赵丹燕,何婷婷,等.绍兴市HIV-1毒株的耐药变异研究[J].中国艾滋病性病,2017,23(4):284-287.
[13] World Health Organization.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection,recommendations for a public health approch,second edition,2016[EB/OL].(2019-11-06)[2021-02-08].https://www.who.int/hiv/pub/arv/arv-2016/en.
[14] 李敬云. HIV耐药的现状、挑战与应对[J].传染病信息,2019,32(6):490-495.
[15] 邵一鸣. HIV耐药监测策略和检测技术[M].北京:人民卫生出版社,2010.
[16] 李扬,邢辉.未治疗艾滋病患者中HIV耐药株的传播研究[J].中华微生物学和免疫学杂志,2016,36(7):540-544.
[17] 阮尉月清,刘家法,张米,等.云南省男男性行为人群HIV/AIDS病例抗病毒治疗失败基因型耐药分析[J].预防医学,2020,32(10):987-991,995.
[18] 谢小慧,于风婷,张霞,等.2019年北京地区HIV-1感染者传播性耐药情况[J].中国艾滋病性病,2020,26(6):579-583.
[19] STERRANTINO G,BORGHI V,CALLEGARO A P,et al.Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors[J].Int J Antimicrob Agents,2019,53(4):515-519. |
|
|
|
